Crinetics Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2021-11-05

Reporting Person: Betz Stephen F. (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-05	Common stock	S	12600	$27.952	Disposed	165615	Direct
2021-11-08	Common stock	S	3900	$28.422	Disposed	161715	Direct

Footnotes

F1: The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date.

F2: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $27.952 per share. The range of sales prices on the transaction date was $27.950 to $27.959 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.

F3: The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $28.422 per share. The range of sales prices on the transaction date was $28.340 to $28.500 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.